LSX-Blog.png

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

Company creation and early-stage investing in life...

There is an abundance of promising scientific research that has the potenti...

Read More

Caution prevails in 2019

How quickly tides can turn – heading into December, 2018 was set to be anot...

Read More

How can a market be both overheated and underinves...

As the saying goes, “Data doesn’t lie…”, except sometimes it does mislead. ...

Read More

Infographic: LSX Investor Perception Survey 2019

Now in its third year, the LSX Investor Perception Survey 2019 tracks the v...

Read More

Life science investors reveal their investment pre...

Around two thirds (61%) of life science investor respondents look for manag...

Read More

The Future of Digital Health: Q&A with Capricorn V...

As new technologies look to play an ever-increasing role in addressing heal...

Read More

Investing in Early-Stage Innovation: Q&A with Sano...

How are established investors working to foster innovation in today’s biote...

Read More

Medtech Investment: Q&A with Panakès Partners’ Ale...

On 5 February 2019, a panel of leading medtech investors will open the 5th ...

Read More

Series A Spotlight: Q&A with Protembis’ Conrad Ras...

In October 2018, German medical device company Protembis closed an oversubs...

Read More

Addex prepares PD-LID programme for 2019 Phase 3 r...

Key findings: Switzerland-based Addex Therapeutics is preparing its lead ca...

Read More

Investorview: Propelling life science innovation f...

Denmark’s Novo Seeds was established in 2007 in order to identify promising...

Read More

Gates Foundation funding for DelSiTech’s silica-ba...

Key learnings: DelSiTech has been awarded significant grant funding from th...

Read More

Add Your Response